SCHEMBL3907489

SCHEMBL3907489

O=C1C(=Cc2ccc(Br)o2)SC(=S)N1c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 13/20 0.67
KMT2A Q03164 13/20 0.67
POLB P06746 10/20 0.67
ALDH1A1 P00352 9/20 0.67
L3MBTL1 Q9Y468 5/20 0.67
CYP1A2 P05177 1/20 0.67
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
MAPT P10636 9/20 0.65
KDM4E B2RXH2 6/20 0.65
MAPK1 P28482 2/20 0.65
THRB P10828 1/20 0.65
MAP3K5 Q99683 1/20 0.56
TDP1 Q9NUW8 4/20 0.56
HPGD P15428 3/20 0.56
RECQL P46063 3/20 0.56
LMNA P02545 3/20 0.56
HTT P42858 2/20 0.56
GAA P10253 1/20 0.56
APEX1 P27695 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907485 1.00 MEN1 (0.67) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL3895693 0.87 MAP3K5 (0.59) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL3895688 0.87 MAP3K5 (0.59) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL8288287 0.85 MEN1 (0.65) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL3908244 0.84 HSD17B3 (0.60) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL3908245 0.84 HSD17B3 (0.60) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL3895634 0.84 POLB (0.72) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL3895627 0.84 POLB (0.72) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL15374280 0.84 POLB (0.72) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL3892037 0.83 MAP3K5 (0.79) MEN1KMT2APOLBALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 WO claimed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MEN1 1562/4885KMT2A 901/4885POLB 2008/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MEN1 2869/4885KMT2A 1020/4885POLB 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.